# A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis

> **NCT07720375** · PHASE2 · RECRUITING · sponsor: **UCB Biopharma SRL** · enrollment: 300 (estimated)

## Conditions studied

- Non-cystic Fibrosis Bronchiectasis

## Interventions

- **BIOLOGICAL:** Galvokimig
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT07720375
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-05
- **Primary completion:** 2029-02-28
- **Final completion:** 2029-04-26
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07720375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07720375, "A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07720375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*